Association of Cancer Stem Cell Markers with Aggressive Tumor Features in Papillary Thyroid Carcinoma

Cancer Facts & Figures 2015. Atlanta, GA: American Cancer Society; 2015. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf. Accessed September 4, 2015.

Ahn S.H. , Henderson Y.C. , Williams M.D. . Detection of thyroid cancer stem cells in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2014; 99(2): 536–544.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. v2.2015. http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. Accessed September 4, 2015.

Guo K. , Wang Z. . Risk factors influencing the recurrence of papillary thyroid carcinoma: a systematic review and meta-analysis. Int J Clin Exp Pathol. 2014; 7(9): 5393–5403.

Hardin H. , Montemayor-Garcia C. , Lloyd R.V. . Thyroid cancer stem-like cells and epithelial-mesenchymal transition in thyroid cancers. Hum Pathol. 2013; 44(9): 1707–1713.

Yun J.Y. , Kim Y.A. , Choe J.Y. . Expression of cancer stem cell markers is more frequent in anaplastic thyroid carcinoma compared to papillary thyroid carcinoma and is related to adverse clinical outcome. J Clin Pathol. 2014; 67(2): 125–133.

Rycaj K. , Tang D.G. . Cell-of-origin of cancer versus cancer stem cells: assays and interpretations. Cancer Res. 2015; 75(19): 4003–4011.

Klonisch T. , Hoang-Vu C. , Hombach-Klonisch S. . Thyroid stem cells and cancer. Thyroid. 2009; 19(12): 1303–1315.

Derwahl M. . Linking stem cells to thyroid cancer. J Clin Endocrinol Metab. 2011; 96(3): 610–613.

Fierabracci A. . Identifying thyroid stem/progenitor cells: advances and limitations. J Endocrinol. 2012; 213(1): 1–13.

Lin R.Y. . Thyroid cancer stem cells. Nat Rev Endocrinol. 2011; 7(10): 609–616.

Davies T.F. , Latif R. , Minsky N.C. . Clinical review: the emerging cell biology of thyroid stem cells. J Clin Endocrinol Metab. 2011; 96(9): 2692–2702.

Hardin H. , Guo Z. , Shan W. . The roles of the epithelial-mesenchymal transition marker PRRX1 and miR-146b-5p in papillary thyroid carcinoma progression. Am J Pathol. 2014; 184(8): 2342–2354.

Tang D.G. . Understanding cancer stem cell heterogeneity and plasticity. Cell Res. 2012; 22(3): 457–472.

Klonisch T. , Wiechec E. , Hombach-Klonisch S. . Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol Med. 2008; 14(10): 450–460.

Nilubol N. , Boufraqech M. , Zhang L. . Loss of CPSF2 expression is associated with increased thyroid cancer cellular invasion and cancer stem cell population, and more aggressive disease. J Clin Endocrinol Metab. 2014; 99(7): E1173–E1182.

He H.C. , Kashat L. , Kak I. . An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma. PLoS One. 2012; 7(9): e42893.

Rehders A. , Anlauf M. , Adamowsky I. . Is minimal residual lymph node disease in papillary thyroid cancer of prognostic impact? An analysis of the epithelial cell adhesion molecule EpCAM in lymph nodes of 40 pN0 patients. Pathol Oncol Res. 2014; 20(1): 185–190.

Edge S.B. , Byrd D.R. , Compton C.C. , eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010: 87–96.

Gires O. . Lessons from common markers of tumor-initiating cells in solid cancers. Cell Mol Life Sci. 2011; 68(24): 4009–4022.

Colak S. , Medema J.P. . Cancer stem cells–important players in tumor therapy resistance. FEBS J. 2014; 281(21): 4779–4791.

Figge J. , del Rosario A.D. , Gerasimov G. . Preferential expression of the cell adhesion molecule CD44 in papillary thyroid carcinoma. Exp Mol Pathol. 1994; 61(13): 203–211.

Ross J.S. , del Rosario A.D. , Sanderson B. . Selective expression of CD44 cell-adhesion molecule in thyroid papillary carcinoma fine-needle aspirates. Diagn Cytopathol. 1996; 14(4): 287–291.

Kim J.Y. , Cho H. , Rhee B.D. . Expression of CD44 and cyclin D1 in fine needle aspiration cytology of papillary thyroid carcinoma. Acta Cytol. 2002; 46(4): 679–683.

Ricci-Vitiani L. , Lombardi D.G. , Pilozzi E. . Identification and expansion of human colon-cancer-initiating cells. Nature. 2007; 445(7123): 111–115.

Friedman S. , Lu M. , Schultz A. . CD133+ anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin. PLoS One. 2009; 4(4): e5395.

Zito G. , Richiusa P. , Bommarito A. . In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. PLoS One. 2008; 3(10): e3544.

Liu J. , Brown R.E. . Immunohistochemical detection of epithelial-mesenchymal transition associated with stemness phenotype in anaplastic thyroid carcinoma. Int J Clin Exp Pathol. 2010; 3(8): 755–762.

Parkin D.M. , Bray F. , Ferlay J. , Pisani P. . Global cancer statistics, 2002. CA Cancer J. Clin. 2005; 55: 74–108.

Went P. , Vasei M. , Bubendorf L. . Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer. 2006; 94(1): 128–135.

Schmelzer E. , Reid L.M. . EpCAM expression in normal, non-pathological tissues. Front Biosci. 2008; 13: 3096–3100.

Ralhan R. , Cao J. , Lim T. . EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis. BMC Cancer. 2010; 10: 331.